Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

Annals of Hematology

Volumn 86, Issue 10, 2007, Pages 749-752

  Carella, Angelo Michele ^a   Lerma, Enrica ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

BCR ABL; CML; Drug intolerance; Drug resistance; Imatinib mesylate; Molecular remission; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; FUROSEMIDE; IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; FLUID RETENTION; FOLLOW UP; HUMAN; HYPOTHESIS; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MUSCLE CRAMP; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34548321398     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0326-2     Document Type: Article

References (10)

1. Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809-1820
2. Barnes DJ, Palaiologou D, Panousopoulou E et al (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65(19):8912-8919
3. Bocchia M, Gentili S, Abruzzese E et al (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 365(9460):657-666
4. Carella AM, Lerma E, Corsetti MT et al (1999) Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 93:1534-1539
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653
6. Gabert J, Beillard E, van Der Velden VHJ et al (2003) Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chin reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia 17:2318-2357
7. Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukemia. Nature 435(7046):1267-1270
8. Kovitz C, Kantarjian H, Garcia-Manero G et al (2006) Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108(8):2811-2813
9. Roeder I, Horn M, Glauche I et al (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 12(10):1181-1184
10. Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 109(1):58-60